From cleared to adopted.
Clearance isn't adoption. Clinicians are skeptical, committees move slowly, and every claim has to stay inside the label. Most medtech marketing goes quiet exactly where it needs to be clearest.
Differentiation that stays inside what's cleared and still says something.
Clinical data turned into the language clinicians, health systems, and payers act on.
Search, conferences, publications: the channels that move a cautious buyer.
Pipeline by stage and source, in the format boards and investors expect.
Device, diagnostics, and digital health companies selling to clinicians and health systems. Typically post-clearance, building the commercial engine from first launch through growth stage.
A commercial teardown: positioning, claims, and visibility against the category.
Weekly operating rhythm with the commercial team.
Evaluations started and accounts won. Not impressions.
“Glenmont’s team is both creative and reliable, always presenting new ideas and executing them seamlessly.”